Netherlands
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.87 (0.70 - 1.04) | 2019 | Modelled | IHME |
0.88 (0.71 - 1.05) | 2018 | Modelled | IHME |
0.9 (0.72 - 1.07) | 2017 | Modelled | IHME |
0.91 (0.75 - 1.08) | 2016 | Modelled | IHME |
0.92 (0.77 - 1.09) | 2015 | Modelled | IHME |
0.92 (0.76 - 1.08) | 2014 | Modelled | IHME |
0.92 (0.76 - 1.08) | 2013 | Modelled | IHME |
0.91 (0.75 - 1.08) | 2012 | Modelled | IHME |
0.91 (0.75 - 1.08) | 2011 | Modelled | IHME |
0.91 (0.73 - 1.08) | 2010 | Modelled | IHME |
0.9 (0.74 - 1.07) | 2009 | Modelled | IHME |
0.9 (0.74 - 1.06) | 2008 | Modelled | IHME |
0.89 (0.74 - 1.05) | 2007 | Modelled | IHME |
0.89 (0.73 - 1.05) | 2006 | Modelled | IHME |
0.89 (0.73 - 1.05) | 2005 | Modelled | IHME |
0.89 (0.74 - 1.05) | 2004 | Modelled | IHME |
0.9 (0.75 - 1.06) | 2003 | Modelled | IHME |
0.91 (0.76 - 1.08) | 2002 | Modelled | IHME |
0.92 (0.77 - 1.09) | 2001 | Modelled | IHME |
0.93 (0.77 - 1.10) | 2000 | Modelled | IHME |
0.93 (0.77 - 1.10) | 1999 | Modelled | IHME |
0.92 (0.76 - 1.09) | 1998 | Modelled | IHME |
0.92 (0.76 - 1.09) | 1997 | Modelled | IHME |
0.91 (0.76 - 1.08) | 1996 | Modelled | IHME |
0.91 (0.75 - 1.09) | 1995 | Modelled | IHME |
0.91 (0.76 - 1.08) | 1994 | Modelled | IHME |
0.92 (0.75 - 1.09) | 1993 | Modelled | IHME |
0.92 (0.76 - 1.09) | 1992 | Modelled | IHME |
0.93 (0.77 - 1.11) | 1991 | Modelled | IHME |
0.94 (0.77 - 1.13) | 1990 | Modelled | IHME |
0.34 (0.22 - 0.47) | 2016 | Survey/reported | Koopsen J et al, 2019 |
0.2 (0.10 - 0.40) | 2007 | Survey/reported | Hahne SJM et al, 2012 |
0.09 (0.07 - 0.11) | 2015 | Modelled | WHO |
0.3 (0.10 - 0.40) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
0.2 (0.10 - 0.40) | 2007 | Survey/reported | ECDC |
0.4 (0.39 - 0.41) | 2013 | Modelled | Schweitzer et al, 2015 |
Showing out of
Show more
Children under-5 years
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.06 (0.04 - 0.07) | 2019 | Modelled | IHME |
0.06 (0.04 - 0.08) | 2018 | Modelled | IHME |
0.06 (0.04 - 0.08) | 2017 | Modelled | IHME |
0.07 (0.05 - 0.09) | 2016 | Modelled | IHME |
0.08 (0.06 - 0.11) | 2015 | Modelled | IHME |
0.12 (0.08 - 0.16) | 2014 | Modelled | IHME |
0.18 (0.12 - 0.24) | 2013 | Modelled | IHME |
0.25 (0.17 - 0.34) | 2012 | Modelled | IHME |
0.31 (0.21 - 0.43) | 2011 | Modelled | IHME |
0.34 (0.22 - 0.47) | 2010 | Modelled | IHME |
0.34 (0.23 - 0.46) | 2009 | Modelled | IHME |
0.34 (0.23 - 0.46) | 2008 | Modelled | IHME |
0.34 (0.23 - 0.45) | 2007 | Modelled | IHME |
0.34 (0.23 - 0.45) | 2006 | Modelled | IHME |
0.34 (0.23 - 0.44) | 2005 | Modelled | IHME |
0.35 (0.24 - 0.46) | 2004 | Modelled | IHME |
0.37 (0.25 - 0.49) | 2003 | Modelled | IHME |
0.4 (0.27 - 0.52) | 2002 | Modelled | IHME |
0.42 (0.28 - 0.55) | 2001 | Modelled | IHME |
0.43 (0.28 - 0.56) | 2000 | Modelled | IHME |
0.43 (0.28 - 0.56) | 1999 | Modelled | IHME |
0.42 (0.27 - 0.56) | 1998 | Modelled | IHME |
0.42 (0.27 - 0.56) | 1997 | Modelled | IHME |
0.42 (0.27 - 0.56) | 1996 | Modelled | IHME |
0.42 (0.27 - 0.55) | 1995 | Modelled | IHME |
0.42 (0.27 - 0.55) | 1994 | Modelled | IHME |
0.42 (0.27 - 0.55) | 1993 | Modelled | IHME |
0.42 (0.27 - 0.55) | 1992 | Modelled | IHME |
0.42 (0.28 - 0.56) | 1991 | Modelled | IHME |
0.43 (0.29 - 0.58) | 1990 | Modelled | IHME |
0.04 (0.03 - 0.05) | 2015 | Modelled | WHO |
Showing out of
Show more
Pregnant women
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.3 (0.30 - 0.40) | 2016 | Modelled | ECDC |
0.3 (0.30 - 0.40) | 2006 | Survey/reported | Op de Coul EL et al, 2011 |
0.3 (0.30 - 0.40) | 2007 | Survey/reported | Op de Coul EL et al, 2011 |
0.4 (0.40 - 0.40) | 2008 | Survey/reported | Op de Coul EL et al, 2011 |
Showing out of
Show more
Men who have sex with men (MSM)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.48 | 2017 | Survey/reported | ECDC Monitoring Report |
0.83 | 2017 | Survey/reported | ECDC Monitoring Report |
0.83 | 2017 | Survey/reported | ECDC |
0.48 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Number of people living with chronic HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
139,736 (114,707 - 168,093) | 1990 | Modelled | IHME |
139,462 (115,147 - 166,726) | 1991 | Modelled | IHME |
139,390 (115,154 - 165,546) | 1992 | Modelled | IHME |
139,535 (114,930 - 165,549) | 1993 | Modelled | IHME |
139,928 (115,902 - 166,026) | 1994 | Modelled | IHME |
140,596 (116,105 - 167,560) | 1995 | Modelled | IHME |
141,662 (117,288 - 168,040) | 1996 | Modelled | IHME |
143,122 (118,822 - 170,076) | 1997 | Modelled | IHME |
144,762 (119,966 - 171,651) | 1998 | Modelled | IHME |
146,317 (121,212 - 173,909) | 1999 | Modelled | IHME |
147,512 (121,758 - 175,533) | 2000 | Modelled | IHME |
147,702 (122,478 - 175,036) | 2001 | Modelled | IHME |
146,838 (121,631 - 173,215) | 2002 | Modelled | IHME |
145,546 (120,732 - 171,618) | 2003 | Modelled | IHME |
144,473 (119,402 - 170,790) | 2004 | Modelled | IHME |
144,301 (118,842 - 171,262) | 2005 | Modelled | IHME |
145,055 (119,604 - 171,554) | 2006 | Modelled | IHME |
146,201 (120,691 - 172,705) | 2007 | Modelled | IHME |
147,589 (121,409 - 175,096) | 2008 | Modelled | IHME |
149,031 (121,843 - 177,081) | 2009 | Modelled | IHME |
150,304 (121,419 - 178,790) | 2010 | Modelled | IHME |
151,515 (124,262 - 179,517) | 2011 | Modelled | IHME |
152,819 (125,829 - 180,725) | 2012 | Modelled | IHME |
154,090 (127,271 - 181,847) | 2013 | Modelled | IHME |
155,212 (128,179 - 182,565) | 2014 | Modelled | IHME |
156,012 (129,694 - 184,706) | 2015 | Modelled | IHME |
155,147 (127,587 - 183,749) | 2016 | Modelled | IHME |
153,200 (122,775 - 181,821) | 2017 | Modelled | IHME |
151,213 (121,996 - 179,506) | 2018 | Modelled | IHME |
148,649 (120,605 - 178,493) | 2019 | Modelled | IHME |
47,000 (25,000 - 68,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
Showing out of
Show more
HBV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
1.65 (1.27 - 2.11) | 2019 | Modelled | IHME |
1.64 (1.26 - 2.10) | 2018 | Modelled | IHME |
1.64 (1.25 - 2.08) | 2017 | Modelled | IHME |
1.62 (1.25 - 2.08) | 2016 | Modelled | IHME |
1.58 (1.22 - 2.03) | 2015 | Modelled | IHME |
1.56 (1.20 - 1.99) | 2014 | Modelled | IHME |
1.58 (1.22 - 2.02) | 2013 | Modelled | IHME |
1.61 (1.25 - 2.06) | 2012 | Modelled | IHME |
1.61 (1.24 - 2.05) | 2011 | Modelled | IHME |
1.62 (1.25 - 2.05) | 2010 | Modelled | IHME |
1.61 (1.24 - 2.04) | 2009 | Modelled | IHME |
1.61 (1.24 - 2.05) | 2008 | Modelled | IHME |
1.6 (1.23 - 2.05) | 2007 | Modelled | IHME |
1.61 (1.24 - 2.10) | 2006 | Modelled | IHME |
1.63 (1.25 - 2.11) | 2005 | Modelled | IHME |
1.67 (1.28 - 2.16) | 2004 | Modelled | IHME |
1.74 (1.34 - 2.26) | 2003 | Modelled | IHME |
1.68 (1.29 - 2.18) | 2002 | Modelled | IHME |
1.63 (1.26 - 2.11) | 2001 | Modelled | IHME |
1.6 (1.24 - 2.07) | 2000 | Modelled | IHME |
1.57 (1.21 - 2.02) | 1999 | Modelled | IHME |
1.52 (1.17 - 1.96) | 1998 | Modelled | IHME |
1.49 (1.15 - 1.93) | 1997 | Modelled | IHME |
1.48 (1.14 - 1.93) | 1996 | Modelled | IHME |
1.46 (1.12 - 1.89) | 1995 | Modelled | IHME |
1.42 (1.09 - 1.84) | 1994 | Modelled | IHME |
1.4 (1.07 - 1.82) | 1993 | Modelled | IHME |
1.35 (1.03 - 1.75) | 1992 | Modelled | IHME |
1.32 (1.02 - 1.70) | 1991 | Modelled | IHME |
1.29 (0.99 - 1.67) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
283 (218 - 362) | 2019 | Modelled | IHME |
281 (216 - 359) | 2018 | Modelled | IHME |
279 (213 - 355) | 2017 | Modelled | IHME |
276 (212 - 353) | 2016 | Modelled | IHME |
268 (206 - 343) | 2015 | Modelled | IHME |
262 (202 - 335) | 2014 | Modelled | IHME |
265 (205 - 339) | 2013 | Modelled | IHME |
270 (208 - 345) | 2012 | Modelled | IHME |
268 (206 - 342) | 2011 | Modelled | IHME |
268 (207 - 341) | 2010 | Modelled | IHME |
267 (205 - 337) | 2009 | Modelled | IHME |
265 (204 - 338) | 2008 | Modelled | IHME |
262 (201 - 336) | 2007 | Modelled | IHME |
264 (203 - 343) | 2006 | Modelled | IHME |
266 (204 - 344) | 2005 | Modelled | IHME |
272 (208 - 351) | 2004 | Modelled | IHME |
282 (216 - 365) | 2003 | Modelled | IHME |
271 (207 - 350) | 2002 | Modelled | IHME |
261 (201 - 338) | 2001 | Modelled | IHME |
254 (197 - 329) | 2000 | Modelled | IHME |
247 (191 - 320) | 1999 | Modelled | IHME |
239 (183 - 308) | 1998 | Modelled | IHME |
233 (180 - 301) | 1997 | Modelled | IHME |
229 (176 - 299) | 1996 | Modelled | IHME |
225 (173 - 292) | 1995 | Modelled | IHME |
218 (167 - 282) | 1994 | Modelled | IHME |
213 (164 - 277) | 1993 | Modelled | IHME |
204 (157 - 265) | 1992 | Modelled | IHME |
198 (153 - 255) | 1991 | Modelled | IHME |
193 (148 - 249) | 1990 | Modelled | IHME |
484 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
11 (8 - 16) | 2019 | Modelled | IHME |
11 (8 - 16) | 2018 | Modelled | IHME |
11 (8 - 16) | 2017 | Modelled | IHME |
11 (8 - 16) | 2016 | Modelled | IHME |
11 (8 - 16) | 2015 | Modelled | IHME |
12 (8 - 17) | 2014 | Modelled | IHME |
12 (8 - 17) | 2013 | Modelled | IHME |
12 (8 - 17) | 2012 | Modelled | IHME |
12 (8 - 17) | 2011 | Modelled | IHME |
12 (8 - 17) | 2010 | Modelled | IHME |
12 (8 - 17) | 2009 | Modelled | IHME |
12 (8 - 17) | 2008 | Modelled | IHME |
12 (8 - 17) | 2007 | Modelled | IHME |
12 (8 - 17) | 2006 | Modelled | IHME |
12 (8 - 17) | 2005 | Modelled | IHME |
12 (8 - 17) | 2004 | Modelled | IHME |
12 (8 - 17) | 2003 | Modelled | IHME |
12 (8 - 17) | 2002 | Modelled | IHME |
12 (8 - 17) | 2001 | Modelled | IHME |
12 (9 - 17) | 2000 | Modelled | IHME |
12 (9 - 17) | 1999 | Modelled | IHME |
12 (9 - 17) | 1998 | Modelled | IHME |
12 (9 - 17) | 1997 | Modelled | IHME |
12 (9 - 18) | 1996 | Modelled | IHME |
12 (9 - 18) | 1995 | Modelled | IHME |
12 (9 - 18) | 1994 | Modelled | IHME |
12 (9 - 18) | 1993 | Modelled | IHME |
12 (9 - 18) | 1992 | Modelled | IHME |
12 (9 - 18) | 1991 | Modelled | IHME |
12 (9 - 18) | 1990 | Modelled | IHME |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
414 (170 - 659) | 2014 | Survey/reported | van Laar M et al, 2014 |
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.48 (0.40 - 0.59) | 2019 | Modelled | IHME |
0.48 (0.39 - 0.58) | 2018 | Modelled | IHME |
0.47 (0.39 - 0.58) | 2017 | Modelled | IHME |
0.47 (0.38 - 0.57) | 2016 | Modelled | IHME |
0.46 (0.38 - 0.56) | 2015 | Modelled | IHME |
0.44 (0.36 - 0.53) | 2014 | Modelled | IHME |
0.4 (0.32 - 0.48) | 2013 | Modelled | IHME |
0.35 (0.29 - 0.42) | 2012 | Modelled | IHME |
0.32 (0.26 - 0.38) | 2011 | Modelled | IHME |
0.3 (0.25 - 0.36) | 2010 | Modelled | IHME |
0.3 (0.25 - 0.36) | 2009 | Modelled | IHME |
0.31 (0.25 - 0.37) | 2008 | Modelled | IHME |
0.31 (0.26 - 0.37) | 2007 | Modelled | IHME |
0.32 (0.27 - 0.38) | 2006 | Modelled | IHME |
0.33 (0.28 - 0.39) | 2005 | Modelled | IHME |
0.36 (0.30 - 0.43) | 2004 | Modelled | IHME |
0.42 (0.34 - 0.50) | 2003 | Modelled | IHME |
0.48 (0.39 - 0.58) | 2002 | Modelled | IHME |
0.53 (0.42 - 0.65) | 2001 | Modelled | IHME |
0.55 (0.44 - 0.68) | 2000 | Modelled | IHME |
0.54 (0.43 - 0.66) | 1999 | Modelled | IHME |
0.5 (0.41 - 0.62) | 1998 | Modelled | IHME |
0.47 (0.38 - 0.57) | 1997 | Modelled | IHME |
0.43 (0.35 - 0.53) | 1996 | Modelled | IHME |
0.41 (0.34 - 0.51) | 1995 | Modelled | IHME |
0.41 (0.33 - 0.50) | 1994 | Modelled | IHME |
0.4 (0.33 - 0.49) | 1993 | Modelled | IHME |
0.4 (0.33 - 0.49) | 1992 | Modelled | IHME |
0.4 (0.32 - 0.49) | 1991 | Modelled | IHME |
0.4 (0.32 - 0.49) | 1990 | Modelled | IHME |
0.1 (0 - 0.20) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.08 (0.03 - 0.13) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.16 (0.06 - 0.27) | 2019 | Survey/reported | Koopsen J et al, 2019 |
0.1 (0 - 0.20) | 2007 | Survey/reported | Vriend HJ et al, 2013 |
0.2 (0.10 - 0.40) | 2014 | Survey/reported | Gower et al, 2014 |
0.22 | 2019 | Modelled | Jin et al. 2017 |
0.1 (0 - 0.20) | 2007 | Survey/reported | ECDC |
Showing out of
Show more
Men who have sex with men (MSM) Living with HIV
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
8.2 (5.10 - 12.10) | 2019 | Modelled | Jin et al. 2017 |
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
55.3 (49.70 - 60.90) | 2017 | Modelled | Degenhardt L et al, 2017 |
39.3 | 2013 | Survey/reported | EMCDDA |
Showing out of
Show more
Men who have sex with men (MSM)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.3 (0.80 - 1.90) | 2003 | Survey/reported | van de Laar TJ et al , 2007 |
0.7 (0.10 - 1.90) | 2007 | Survey/reported | Van Rooijen MS et al , 2013 |
4.8 | 2017 | Survey/reported | ECDC |
3.7 | 2019 | Modelled | Jin et al. 2017 |
Showing out of
Show more
Number of people living with chronic HCV (RNA+/cAg)
National
DownloadValue | Year | Type | Source |
---|---|---|---|
59,046 (48,130 - 72,716) | 1990 | Modelled | IHME |
59,576 (48,646 - 73,538) | 1991 | Modelled | IHME |
60,320 (49,356 - 74,082) | 1992 | Modelled | IHME |
61,249 (50,152 - 75,059) | 1993 | Modelled | IHME |
62,336 (51,180 - 76,969) | 1994 | Modelled | IHME |
63,555 (51,896 - 78,137) | 1995 | Modelled | IHME |
66,740 (54,531 - 81,455) | 1996 | Modelled | IHME |
72,571 (58,952 - 88,392) | 1997 | Modelled | IHME |
79,242 (64,022 - 96,684) | 1998 | Modelled | IHME |
84,879 (68,091 - 103,986) | 1999 | Modelled | IHME |
87,559 (69,550 - 107,899) | 2000 | Modelled | IHME |
84,715 (67,889 - 103,508) | 2001 | Modelled | IHME |
76,988 (62,661 - 93,265) | 2002 | Modelled | IHME |
67,293 (55,588 - 80,656) | 2003 | Modelled | IHME |
58,614 (48,986 - 69,601) | 2004 | Modelled | IHME |
54,004 (45,004 - 64,237) | 2005 | Modelled | IHME |
52,551 (43,625 - 62,548) | 2006 | Modelled | IHME |
51,347 (42,579 - 61,187) | 2007 | Modelled | IHME |
50,470 (41,594 - 60,202) | 2008 | Modelled | IHME |
49,985 (40,902 - 59,921) | 2009 | Modelled | IHME |
49,950 (40,813 - 60,116) | 2010 | Modelled | IHME |
52,655 (42,988 - 63,030) | 2011 | Modelled | IHME |
58,946 (48,289 - 70,376) | 2012 | Modelled | IHME |
66,694 (54,484 - 79,844) | 2013 | Modelled | IHME |
73,746 (60,159 - 88,823) | 2014 | Modelled | IHME |
77,889 (63,469 - 94,357) | 2015 | Modelled | IHME |
79,472 (65,280 - 96,296) | 2016 | Modelled | IHME |
80,656 (66,077 - 98,152) | 2017 | Modelled | IHME |
81,738 (67,041 - 99,584) | 2018 | Modelled | IHME |
82,650 (67,911 - 101,039) | 2019 | Modelled | IHME |
16,000 (5,000 - 26,000) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue | Year | Type | Source |
---|---|---|---|
3,000 (940 - 4,600) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
DownloadValue (Deaths per 100,000) | Year | Type | Source |
---|---|---|---|
3.62 (2.86 - 4.43) | 2019 | Modelled | IHME |
3.56 (2.81 - 4.36) | 2018 | Modelled | IHME |
3.52 (2.76 - 4.31) | 2017 | Modelled | IHME |
3.5 (2.80 - 4.29) | 2016 | Modelled | IHME |
3.4 (2.69 - 4.19) | 2015 | Modelled | IHME |
3.29 (2.59 - 4.05) | 2014 | Modelled | IHME |
3.24 (2.58 - 3.99) | 2013 | Modelled | IHME |
3.2 (2.57 - 3.95) | 2012 | Modelled | IHME |
3.09 (2.46 - 3.81) | 2011 | Modelled | IHME |
3.03 (2.40 - 3.72) | 2010 | Modelled | IHME |
2.99 (2.38 - 3.67) | 2009 | Modelled | IHME |
2.96 (2.37 - 3.63) | 2008 | Modelled | IHME |
2.91 (2.33 - 3.58) | 2007 | Modelled | IHME |
2.91 (2.30 - 3.59) | 2006 | Modelled | IHME |
2.9 (2.29 - 3.60) | 2005 | Modelled | IHME |
2.95 (2.33 - 3.66) | 2004 | Modelled | IHME |
3.04 (2.41 - 3.77) | 2003 | Modelled | IHME |
2.95 (2.33 - 3.65) | 2002 | Modelled | IHME |
2.85 (2.27 - 3.56) | 2001 | Modelled | IHME |
2.78 (2.21 - 3.50) | 2000 | Modelled | IHME |
2.73 (2.17 - 3.39) | 1999 | Modelled | IHME |
2.66 (2.12 - 3.29) | 1998 | Modelled | IHME |
2.61 (2.09 - 3.22) | 1997 | Modelled | IHME |
2.56 (2.05 - 3.17) | 1996 | Modelled | IHME |
2.53 (2.01 - 3.14) | 1995 | Modelled | IHME |
2.46 (1.95 - 3.05) | 1994 | Modelled | IHME |
2.42 (1.92 - 3) | 1993 | Modelled | IHME |
2.33 (1.86 - 2.91) | 1992 | Modelled | IHME |
2.27 (1.81 - 2.83) | 1991 | Modelled | IHME |
2.23 (1.77 - 2.78) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
621 (491 - 760) | 2019 | Modelled | IHME |
609 (480 - 746) | 2018 | Modelled | IHME |
599 (471 - 734) | 2017 | Modelled | IHME |
595 (476 - 728) | 2016 | Modelled | IHME |
575 (455 - 708) | 2015 | Modelled | IHME |
554 (437 - 683) | 2014 | Modelled | IHME |
543 (433 - 670) | 2013 | Modelled | IHME |
535 (430 - 661) | 2012 | Modelled | IHME |
516 (410 - 635) | 2011 | Modelled | IHME |
503 (398 - 618) | 2010 | Modelled | IHME |
495 (394 - 607) | 2009 | Modelled | IHME |
487 (391 - 598) | 2008 | Modelled | IHME |
478 (382 - 587) | 2007 | Modelled | IHME |
476 (377 - 587) | 2006 | Modelled | IHME |
473 (373 - 587) | 2005 | Modelled | IHME |
479 (378 - 594) | 2004 | Modelled | IHME |
492 (389 - 609) | 2003 | Modelled | IHME |
474 (375 - 586) | 2002 | Modelled | IHME |
456 (363 - 569) | 2001 | Modelled | IHME |
442 (351 - 556) | 2000 | Modelled | IHME |
431 (343 - 536) | 1999 | Modelled | IHME |
417 (333 - 516) | 1998 | Modelled | IHME |
407 (326 - 502) | 1997 | Modelled | IHME |
398 (317 - 492) | 1996 | Modelled | IHME |
390 (311 - 484) | 1995 | Modelled | IHME |
376 (299 - 467) | 1994 | Modelled | IHME |
368 (292 - 457) | 1993 | Modelled | IHME |
352 (281 - 441) | 1992 | Modelled | IHME |
342 (272 - 426) | 1991 | Modelled | IHME |
332 (264 - 415) | 1990 | Modelled | IHME |
634 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
35 (27 - 44) | 2019 | Modelled | IHME |
35 (26 - 44) | 2018 | Modelled | IHME |
35 (26 - 44) | 2017 | Modelled | IHME |
35 (26 - 44) | 2016 | Modelled | IHME |
35 (26 - 43) | 2015 | Modelled | IHME |
35 (26 - 43) | 2014 | Modelled | IHME |
34 (26 - 43) | 2013 | Modelled | IHME |
34 (26 - 43) | 2012 | Modelled | IHME |
34 (26 - 43) | 2011 | Modelled | IHME |
34 (26 - 42) | 2010 | Modelled | IHME |
34 (26 - 42) | 2009 | Modelled | IHME |
34 (26 - 42) | 2008 | Modelled | IHME |
34 (26 - 42) | 2007 | Modelled | IHME |
34 (26 - 42) | 2006 | Modelled | IHME |
34 (26 - 42) | 2005 | Modelled | IHME |
34 (26 - 42) | 2004 | Modelled | IHME |
34 (25 - 42) | 2003 | Modelled | IHME |
34 (25 - 42) | 2002 | Modelled | IHME |
34 (25 - 42) | 2001 | Modelled | IHME |
34 (25 - 42) | 2000 | Modelled | IHME |
34 (25 - 42) | 1999 | Modelled | IHME |
34 (26 - 42) | 1998 | Modelled | IHME |
34 (26 - 42) | 1997 | Modelled | IHME |
34 (26 - 42) | 1996 | Modelled | IHME |
34 (25 - 42) | 1995 | Modelled | IHME |
34 (26 - 42) | 1994 | Modelled | IHME |
34 (25 - 43) | 1993 | Modelled | IHME |
34 (25 - 43) | 1992 | Modelled | IHME |
34 (26 - 43) | 1991 | Modelled | IHME |
34 (25 - 43) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
414 (170 - 659) | 2014 | Survey/reported | van Laar M et al, 2014 |
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Overview
HBV elimination goal
HCV elimination goal
Hepatitis related deaths (national)
Prevalence < 5
HBV
0.06
(%)
2019, latest modelled
(0.04 - 0.07(%))
IHME
Prevalence PWID
HCV
39.30
(%)
2013, survey/surveillance
EMCDDA
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines